Clinical Trials

81 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04802590 2026-03-04

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

194 enrolled

Lymphoma, Mantle-Cell

NCT01880567 2026-02-19

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

113 enrolled

Lymphoma, Mantle-Cell

NCT02756897 2026-02-19

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

234 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03198026 2026-02-19

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

30 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT03710772 2026-02-11

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Lymphoma, Mantle-Cell

NCT03282396 2026-02-06

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

20 enrolled

Lymphoma, Mantle-Cell

NCT03513562 2026-02-06

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

28 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03697512 2026-01-15

MALIBU

175 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT02518555 2026-01-07

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

42 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

112 enrolled

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT03620903 2025-12-05

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

53 enrolled

Waldenstrom Macroglobulinemia

NCT03734198 2025-11-26

IDA53

29 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02427620 2025-11-21

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

131 enrolled

Lymphoma, Mantle-Cell

NCT02251548 2025-10-24

iFCR

85 enrolled 17 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01849263 2025-09-10

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

41 enrolled 12 charts

Lymphoma, Follicular

NCT02581930 2025-09-08

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

18 enrolled 10 charts

Dermatologic

Melanoma

NCT04273139 2025-07-30

Ibrutinib + Venetoclax in Untreated WM

45 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT01589302 2025-07-25

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

154 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT03646461 2025-04-06

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

5 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04263480 2025-04-04

CZAR-1

99 enrolled

Waldenstrom Macroglobulinemia, Neoplasms

NCT04234061 2024-11-07

TARMAC

20 enrolled

Lymphoma, B-Cell

NCT01500733 2024-09-19

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

86 enrolled 10 charts

Leukemia, Leukemia, Lymphoid, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02514083 2024-09-19

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

29 enrolled 11 charts